Floatz logo

ag-120

CRC

Fudan UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the CRC cohort.

Asset / SponsorPhaseRating
ngm707
NGM Biopharmaceuticals, Inc
Phase 2B
Irinotecan
Chang Gung Memorial Hospital
Phase 2B
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937
Cardiff Oncology
Phase 2B
Tunlametinib
Chinese PLA General Hospital
Phase 2CCC
GENETICALLY-MODIFIED ONCOLYTIC TYPE 5 ADENOVIRUS WHICH SELECTIVELY REPLICATES IN TUMOR CELLS CONTAINING DYSFUNCTIONAL P53 GENE (H101)
Jun Huang
Phase 2CCC

View all 21 →

Same molecule, other indications

ag-120 is also rated in:

acute myeloid leukemia with multilineage dysplasiaDormant
BB
Indicative ·
66 / 100
View asset →
IDH1 MutationDormant
BB
Indicative ·
64 / 100
View asset →
myeloproliferative neoplasmDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →